Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 University of Colorado Cancer Center;
  • 2 Moffitt Cancer Center;
  • 3 Huntsman Cancer Institute at the University of Utah;
  • 4 Patient Advocate;
  • 5 Mayo Clinic Cancer Center;
  • 6 Stanford Cancer Institute;
  • 7 Vanderbilt-Ingram Cancer Center;
  • 8 University of Wisconsin Carbone Cancer Center;
  • 9 Massachusetts General Hospital Cancer Center;
  • 10 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 11 Fox Chase Cancer Center;
  • 12 Roswell Park Comprehensive Cancer Center;
  • 13 Abramson Cancer Center at the University of Pennsylvania;
  • 14 Memorial Sloan Kettering Cancer Center;
  • 15 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 16 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 17 Duke Cancer Institute;
  • 18 University of Michigan Rogel Cancer Center;
  • 19 UC San Diego Moores Cancer Center;
  • 20 Fred & Pamela Buffett Cancer Center;
  • 21 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • 22 O'Neal Comprehensive Cancer Center at UAB;
  • 23 City of Hope National Medical Center;
  • 24 St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;
  • 25 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 26 Dana-Farber/Brigham and Women’s Cancer Center;
  • 27 The University of Texas MD Anderson Cancer Center;
  • 28 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; and
  • 29 National Comprehensive Cancer Network
Restricted access

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

Individual Disclosures for the NCCN Bladder Cancer Panel

TU1

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:734.

  • 2.

    Cancer Stat Facts. Bladder Cancer. NIH NCI: Surveillance, Epidemiology, and End Results Program; 2019. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed June 20, 2019.

  • 3.

    DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician 2017;96:507514.

  • 4.

    Xu Y, Huo R, Chen X, . Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 2017;96:e8588.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Antoni S, Ferlay J, Soerjomataram I, . Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71:96108.

  • 6.

    Hu J, Chen JB, Cui Y, . Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11596.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Carlo MI, Ravichandran V, Srinavasan P, . Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. J Clin Oncol 2019;38:JCO1901395.

    • Search Google Scholar
    • Export Citation
  • 8.

    Welty CJ, Wright JL, Hotaling JM, . Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. Urol Oncol 2014;32:25.e2125.e25.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Messing EM, Tangen CM, Lerner SP, . Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non–muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 2018;319:18801888.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, . Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: A prospective multicentre randomised study in 2243 patients. Eur Urol 2018;73:226232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Sylvester RJ, Oosterlinck W, Holmang S, . Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation? Eur Urol 2016;69:231244.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    van der Meijden A, Oosterlinck W, Brausi M, . Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1999;35:267271.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Amin MB, Edge SB, Greene F, , editors. AJCC Cancer Staging Manual, 8th Ed. New York: Springer International Publishing; 2017.

  • 14.

    American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline. 2016. Available at: https://www.auanet.org/guidelines/bladder-cancer-non-muscle-invasive-guideline. Accessed June 20, 2019.

  • 15.

    Pasin E, Josephson DY, Mitra AP, . Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008;10:3143.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Sylvester RJ, van der Meijden AP, Oosterlinck W, . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466465, discussion 475–477.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Edge SB, Byrd DR, Compton CC, , editors. AJCC Cancer Staging Manual, 7th Ed. New York: Springer; 2010.

  • 18.

    Schmidbauer J, Witjes F, Schmeller N, . Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135138.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Jocham D, Witjes F, Wagner S, . Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862866., discussion 866.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Grossman HB, Gomella L, Fradet Y, . A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:6267.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Fradet Y, Grossman HB, Gomella L, . A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:6873., discussion 73.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Stenzl A, Burger M, Fradet Y, . Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:19071913.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Hermann GG, Mogensen K, Carlsson S, . Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011;108(8b):E297E303.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Yuan H, Qiu J, Liu L, . Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One 2013;8:e74142.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Burger M, Grossman HB, Droller M, . Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846854.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Rink M, Babjuk M, Catto JW, . Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 2013;64:624638.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Kamat AM, Cookson M, Witjes JA, . The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer 2016;2:273278.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Cauberg EC, Kloen S, Visser M, . Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology 2010;76:658663.

  • 29.

    Chen G, Wang B, Li H, . Applying narrow-band imaging in complement with white-light imaging cystoscopy in the detection of urothelial carcinoma of the bladder. Urol Oncol 2013;31:475479.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Geavlete B, Jecu M, Multescu R, . Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Ther Adv Urol 2012;4:211217.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Shen YJ, Zhu YP, Ye DW, . Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a “second look” matters? Int Urol Nephrol 2012;44:451457.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Tatsugami K, Kuroiwa K, Kamoto T, . Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol 2010;24:18071811.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Naselli A, Introini C, Timossi L, . A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol 2012;61:908913.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Naito S, Algaba F, Babjuk M, . The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-sssisted TURBT in primary non-muscle-invasive bladder cancer patients: Trial protocol and 1-year results. Eur Urol 2016;70:506515.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Xiong Y, Li J, Ma S, . A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One 2017;12:e0170819.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Kang W, Cui Z, Chen Q, . Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget 2017;8:2388023890.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102:11111114.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Jones G, Cleves A, Wilt TJ, . Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294.

  • 39.

    Sylvester RJ, van der Meijden AP, Witjes JA, . Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:8691., discussion 91–92.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180183.

  • 41.

    Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:9095.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:12161223.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Shelley MD, Kynaston H, Court J, . A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209216.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Shelley MD, Wilt TJ, Court J, . Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485490.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Malmström PU, Sylvester RJ, Crawford DE, . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247256.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Spencer BA, McBride RB, Hershman DL, . Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:9298.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Järvinen R, Kaasinen E, Sankila A, . Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260265.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Gontero P, Oderda M, Mehnert A, . The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 2013;190:857862.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Sylvester RJ, Brausi MA, Kirkels WJ, . Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766773.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Duchek M, Johansson R, Jahnson S, . Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer: a prospective, randomized, Nordic study. Eur Urol 2010;57:2531.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Lamm DL, Blumenstein BA, Crissman JD, . Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:11241129.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579585.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Oddens J, Brausi M, Sylvester R, . Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462472.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682686, discussion 686–687.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:19641970.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    U.S. Food and Drug Administration. Prescribing Information. TICE® (BCG live), for intravesical use. 2009. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf. Accessed June 20, 2019.

  • 57.

    van der Meijden AP, Sylvester RJ, Oosterlinck W, . Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer genito-urinary group phase III trial. Eur Urol 2003;44:429434.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58.

    Colombel M, Saint F, Chopin D, . The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935939.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Damiano R, De Sio M, Quarto G, . Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity? BJU Int 2009;104:633639.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Brausi M, Oddens J, Sylvester R, . Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:6976.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Lebret T, Bohin D, Kassardjian Z, . Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 2000;163:6367.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, . Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:12421247.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Mugiya S, Ozono S, Nagata M, . Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005;35:395399.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Bandari J, Maganty A, MacLeod LC, . Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Guérin. Eur Urol Focus 2018;4:481484.

  • 65.

    Shortage Notice BCG. American Urological Association (AUA), American Association of Clinical Urologists (AACU), Bladder Cancer Advocacy Network (BCAN), Society of Urologic Oncology (SUO), the Large Urology Group Practice Association (LUGPA), and the Urology Care Foundation (UCF); 2019. Available at: https://www.auanet.org/bcg-shortage-notice. Accessed March 4, 2019.

  • 66.

    Di Lorenzo G, Perdonà S, Damiano R, . Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010;116:18931900.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 67.

    Friedrich MG, Pichlmeier U, Schwaibold H, . Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52:11231129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Chou R, Selph S, Buckley DI, . Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197:11891199.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    van der Meijden AP, Brausi M, Zambon V, . Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001;166:476481.

    • Search Google Scholar
    • Export Citation
  • 70.

    Steinberg G, Bahnson R, Brosman S, . Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol 2000;163:761767.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 2009;27:331335.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Milbar N, Kates M, Chappidi MR, . Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 2017;3:293303.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Breyer BN, Whitson JM, Carroll PR, . Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010;28:510514.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Klaassen Z, Kamat AM, Kassouf W, . Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: New insights and updated recommendations. Eur Urol 2018;74:597608.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Pfister C, Kerkeni W, Rigaud J, . Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol 2015;22:5360.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Yokomizo A, Kanimoto Y, Okamura T, . Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer. J Urol 2016;195:4146.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Balar AV, Kulkarni GS, Uchio EM, . Keynote 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) [abstract]. J Clin Oncol 2019;37(Suppl):350.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    U. S. Food and Drug Administration. Prescribing Information. KEYTRUDA® (pembrolizumab) injection, for intravenous use. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s067lbl.pdf. Accessed January 17, 2020.

  • 79.

    Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21(1B):765769.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Huncharek M, Geschwind JF, Witherspoon B, . Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676680.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Grimm MO, Steinhoff C, Simon X, . Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433437.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:7476.

  • 83.

    Ramírez-Backhaus M, Domínguez-Escrig J, Collado A, . Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep 2012;13:109114.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Divrik RT, Yildirim U, Zorlu F, . The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:16411644.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:12961299.

  • 86.

    Mari A, Kimura S, Foerster B, . A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123:1121.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Gofrit ON, Pode D, Lazar A, . Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006;49:303306., discussion 306–307.

  • 88.

    Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170:438441.

  • 89.

    Chou R, Gore JL, Buckley D, . Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med 2015;163:922931.

  • 90.

    Skinner EC, Goldman B, Sakr WA, . SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol 2013;190:12001204.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Raj GV, Herr H, Serio AM, . Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177:12831286., discussion 1286.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Raj GV, Iasonos A, Herr H, . Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006;24:30953100.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Sweeney P, Millikan R, Donat M, . Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169:21132117.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 94.

    Otto T, Krege S, Suhr J, . Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 2001;57:5559.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95.

    Siefker-Radtke AO, Walsh GL, Pisters LL, . Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004;171:145148.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96.

    Lehmann J, Suttmann H, Albers P, . Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009;55:12931299.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Dodd PM, McCaffrey JA, Herr H, . Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999;17:25462552.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Abe T, Shinohara N, Harabayashi T, . Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007;52:11061113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Ho PL, Willis DL, Patil J, . Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol 2016;34:59.e159.e8.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 100.

    Patel V, Collazo Lorduy A, Stern A, . Survival after metastasectomy for metastatic urothelial carcinoma: A systematic review and meta-analysis. Bladder Cancer 2017;3:121132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Faltas BM, Gennarelli RL, Elkin E, . Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol 2018;36:9.e119.e17.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102.

    Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA). 2019. Available at: https://www.cms.gov/regulations-and-guidance/legislation/clia/index.html. Accessed June 18, 2019.

  • 103.

    U.S. Food & Drug Administration. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. 2019. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma. Accessed June 18, 2019.

  • 104.

    U.S. Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). 2019. Available at: https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools. Accessed July 9, 2019.

  • 105.

    U. S. Food and Drug Administration. FDA Alerts Health Care Professionals and Oncology Clinical Investigators about an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1. 2018. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm. Accessed June 20, 2019.

  • 106.

    Alexandrov LB, Nik-Zainal S, Wedge DC, . Signatures of mutational processes in human cancer. Nature 2013;500:415421.

  • 107.

    Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315322.

  • 108.

    Ross JS, Wang K, Khaira D, . Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 2016;122:702711.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Kaufman D, Raghavan D, Carducci M, . Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:19211927.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    von der Maase H, Sengelov L, Roberts JT, . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:46024608.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 111.

    Sternberg CN, de Mulder PH, Schornagel JH, . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:26382646.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Sternberg CN, de Mulder P, Schornagel JH, . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:5054.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    von der Maase H, Hansen SW, Roberts JT, . Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:30683077.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 114.

    De Santis M, Bellmunt J, Mead G, . Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol 2009;27:56345639.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 115.

    Vaughn DJ, Broome CM, Hussain M, . Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937940.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Sideris S, Aoun F, Zanaty M, . Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol 2016;4:10631067.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Papamichael D, Gallagher CJ, Oliver RT, . Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606607.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    McCaffrey JA, Hilton S, Mazumdar M, . Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:18531857.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Bellmunt J, von der Maase H, Mead GM, . Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30:11071113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Burch PA, Richardson RL, Cha SS, . Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 2000;164:15381542.

  • 121.

    Meluch AA, Greco FA, Burris HA III, . Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;19:30183024.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Bellmunt J, Guillem V, Paz-Ares L, . Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000;18:32473255.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Hussain M, Vaishampayan U, Du W, . Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:25272533.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Pectasides D, Glotsos J, Bountouroglou N, . Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002;13:243250.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 125.

    De Santis M, Bellmunt J, Mead G, . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191199.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 126.

    Bellmunt J, Théodore C, Demkov T, . Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:44544461.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Garon EB, Rizvi NA, Hui R, . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:20182028.

  • 128.

    Brahmer J, Reckamp KL, Baas P, . Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123135.

  • 129.

    Postow MA, Chesney J, Pavlick AC, . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:20062017.

  • 130.

    Larkin J, Chiarion-Sileni V, Gonzalez R, . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:2334.

  • 131.

    Wolchok JD, Kluger H, Callahan MK, . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122133.

  • 132.

    Le DT, Uram JN, Wang H, . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:25092520.

  • 133.

    Kamat AM, Bellmunt J, Galsky MD, . Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 2017;5:68.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Plimack ER, Bellmunt J, Gupta S, . Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017;18:212220.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Bellmunt J, de Wit R, Vaughn DJ, Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:10151026.

  • 136.

    Fradet Y, Bellmunt J, Vaughn DJ, . Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 2019;30:970976.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Balar AV, Castellano D, O’Donnell PH, . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:14831492.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Rosenberg JE, Hoffman-Censits J, Powles T, . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:19091920.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Necchi A, Joseph RW, Loriot Y, . Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol 2017;28:30443050.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Powles T, Durán I, van der Heijden MS, . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748757.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Sternberg CN, Loriot Y, James N, . Primary results from SAUL, a multinational ingle-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019;76:7381.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Pal SK, Hoffman-Censits J, Zheng H, . Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: clinical experience from an expanded access study in the United States. Eur Urol 2018;73:800806.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Balar AV, Galsky MD, Rosenberg JE, . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:6776.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    U. S. Food and Drug Administration. Prescribing Information. TECENTRIQ® (atezolizumab) injection, for intravenous use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s014lbl.pdf. Accessed June 20, 2019.

  • 145.

    Sharma P, Retz M, Siefker-Radtke A, . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312322.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Sharma P, Callahan MK, Bono P, . Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17:15901598.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Sharma P, Siefker-Radtke A, de Braud F, . Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J Clin Oncol 2019;37:16081616.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Massard C, Gordon MS, Sharma S, . Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:31193125.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Powles T, O’Donnell PH, Massard C, . Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Apolo AB, Infante JR, Balmanoukian A, . Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol 2017;35:21172124.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Patel MR, Ellerton J, Infante JR, . Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:5164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Loriot Y, Necchi A, Park SH, . Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338348.

  • 153.

    U. S. Food and Drug Administration. Prescribing Information. BALVERSA (erdafitinib) tablets, for oral use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. Accessed January 7, 2020.

  • 154.

    Rosenberg JE, O’Donnell PH, Balar AV, . Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37:25922600.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 11825 11825 1013
PDF Downloads 4126 4126 304
EPUB Downloads 0 0 0